A plausible intervention based on preclinical science — but not a proven one based on human clinical trials. Here is what the evidence actually says.
NAD+ therapy and "longevity medicine" have moved from biohacking forums to mainstream telehealth platforms in under two years. In 2026, you can order NAD+ infusions, subcutaneous injections, or oral supplements through multiple virtual health services — often bundled with peptide therapy, hormone optimization, and metabolic panel monitoring.
The question is whether any of this is worth the money.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell. It plays a central role in cellular energy production, DNA repair, and the function of sirtuins — proteins associated with aging and longevity in preclinical research.
NAD+ levels decline with age. This is established. What is not established is whether supplementing NAD+ produces clinically meaningful benefits in humans. The research landscape looks like this:
The typical telehealth longevity program includes some combination of biomarker testing (metabolic panels, inflammatory markers, hormone levels), NAD+ supplementation or injection, peptide therapy (BPC-157, sermorelin, and others), lifestyle and nutrition guidance, and ongoing monitoring.
Pricing ranges from $200–$800/month depending on the platform, the specific therapies included, and whether at-home injection supplies are bundled or billed separately.
NAD+ therapy and longevity services through telehealth with clinical oversight.
NAD+ programs available · Pricing on consultation
Paid link · Affiliate disclosure
Compounded NAD+ preparations are not FDA-approved. They are prepared by state-licensed pharmacies for individual patient use.
Many longevity telehealth platforms bundle NAD+ with peptide therapy — injectable peptides that are claimed to promote healing, muscle growth, immune function, or hormone optimization. The regulatory status of many therapeutic peptides is complex. Some (like semaglutide) are FDA-approved for specific indications. Others (like BPC-157) have no FDA approval, limited human trial data, and exist in a regulatory gray area when prescribed through compounding pharmacies.
Patients should understand that peptide therapy prescribed through telehealth longevity programs is largely outside the mainstream evidence base. This does not mean it is ineffective — it means the evidence to confirm or deny effectiveness does not yet exist in sufficient quantity.
Longevity medicine through telehealth serves a specific demographic: generally healthy, financially comfortable individuals who are optimizing rather than treating disease. There is nothing wrong with optimization as a goal. The problem arises when platforms market optimization as medicine, making implicit health claims that the evidence does not support.
If you are considering a telehealth longevity program, the questions to ask are: What specific biomarkers will be tracked? What is the evidence base for each intervention? What would success look like, and how will we measure it? And — critically — what would make us stop if it is not working?
NAD+ and longevity telehealth is a fast-growing market built on promising but incomplete science. Patients who go in with realistic expectations, financial comfort with the cost, and a provider who is honest about the evidence gaps can make informed decisions. Patients who are told NAD+ will "reverse aging" or "prevent disease" are being marketed to, not treated.
Affiliate Disclosure: Virtual Health Visits earns commissions when readers sign up through certain links. This does not influence our coverage, rankings, or editorial independence. We review providers with and without affiliate programs equally.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication or treatment program.